Cannabidiol as a Prospective Therapy for Anxiety Disorders.
Blessing EM1, Steenkamp MM2, Manzanares J2,three, Marmar CR2.
Author information and facts
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in current years has drawn growing interest as a therapy for a variety of neuropsychiatric disorders. The objective of the present evaluation is to identify CBD‘s prospective as a therapy for anxiousness-related disorders, by assessing proof from preclinical, human experimental, clinical, and epidemiological research. We located that current preclinical proof strongly supports CBD as a therapy for generalized anxiousness disorder, panic disorder, social anxiousness disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely nonetheless, couple of research have investigated chronic CBD dosing. Likewise, proof from human research supports an anxiolytic part of CBD, but is presently restricted to acute dosing, also with couple of research in clinical populations. All round, present proof indicates CBD has considerable prospective as a therapy for various anxiety disorders, with need to have for additional study of chronic and therapeutic effects in relevant clinical populations.
Anxiety Cannabidiol Endocannabinoids Generalized anxiousness disorder Post-traumatic stress disorder